ITRM Share Price Performance
US$0.39
-1.28 (-76.70%)
80.5% undervalued intrinsic discount
US$2.00
Fair Value
Price US$0.39
AnalystLowTarget US$2.00
Fair ValueUS$2.00
Share Pricen/a
Iterum Therapeutics plc Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
ITRM Community Narratives
AN
Fair Value US$2 80.5% undervalued intrinsic discount
Antibiotic Resistance And Payer Access Challenges Will Eventually Support A Cautious Long-Term Recovery
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Antibiotic Resistance And Payer Access Challenges Will Eventually Support A Cautious Long-Term Recovery
Catalysts About Iterum Therapeutics Iterum Therapeutics is a commercial stage pharmaceutical company focused on marketing ORLYNVAH, an oral antibiotic for uncomplicated urinary tract infections in the United States. What are the underlying business or industry changes driving this perspective?Read more
7
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$2
80.5% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
350.52% p.a.
Profit Margin
20.88%
Future PE
21.74x
Price in 2028
US$1.4
Trending Discussion
Recently Updated Narratives
AN
Antibiotic Resistance And Payer Access Challenges Will Eventually Support A Cautious Long-Term Recovery
Fair Value: US$2 80.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Iterum Therapeutics plc Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.51
- 29.74%
- -6,913.08%
- -457.1%
About ITRM
- Founded
- 2015
- Employees
- 9
- CEO
- WebsiteView website
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
